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Abstract Tau proteins aggregate into different neuronal inclu-
sions in several neurodegenerative disorders. In Alzheimer's 
disease (AD), hyperphosphorylated Tau from paired helical 
filaments (PHF) of neurofibrillary tangles, named PHF-Tau, 
have an electrophoretic profile with four main bands (Tau 55, 64, 
69, 74 kDa). In Pick's disease, phosphorylated Tau from Pick 
bodies are made of two major components (Tau 55, 64 kDa) and 
a minor 69 kDa. Here we show, using specific antibodies against 
translated exon 2, 3 or 10 of Tau isoforms, that the set of Tau 
isoforms engaged in the most insoluble part of PHF in AD is 
made of Tau isoforms with exon 10 while they are lacking in 
phosphorylated Tau from Pick's disease. Our results suggest that 
specific sets of Tau isoforms distinguish between typical neuronal 
inclusions. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Paired helical filaments (PHF) are the main structural com-
ponents found in degenerating neurons of Alzheimer's disease 
(AD). These pathological filaments are composed of abnor-
mally hyperphosphorylated Tau proteins, named PHF-Tau or 
pathological Tau proteins [1-4]. In many other neurodegener-
ative diseases, Tau-positive inclusions are also observed (for 
review see [4]), including corticobasal degeneration [5], pro-
gressive supranuclear palsy [6,7], amyotrophic lateral sclerosis/ 
parkisonism-dementia complex of Guam [8,9], myotonic dys-
trophy [10] and Pick's disease (PiD) [5,11]. Tau protein aggre-
gation is associated with neurofibrillary degeneration (NFD) 
and the presence of degenerating neurons in neocortical asso-
ciation areas is well correlated with cognitive impairment [12]. 
Interestingly, the Tau profile is disease specific [4]. For exam-
ple, pathological Tau are composed of four main components 
(Tau 74, 69, 64 and 55 kDa) in AD whereas they are made of 
two major components (Tau 64, 55 kDa) and a minor Tau 69 
kDa in PiD [4,11]. 
Tau are phosphoproteins which belong to the family of 
microtubule-associated protein. In human brain, alternative 
mRNA splicing of a single gene transcript generates six Tau 
isoforms [13]. These isoforms differ by the insertion of 29 or 
58 amino acids, translated from exon 2 or exons 2 and 3, near 
the amino-terminal part, and/or by the insertion of a fourth 
microtubule-binding motif translated from exon 10, at the half 
carboxy-terminal part of Tau. 
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In vitro studies have recently shown that Tau isoforms with 
three microtubule-binding motifs aggregate more efficiently 
into PHF-like structure, in the presence of heparin, sulfated 
glycosaminoglycans or RNAs [14-16]. In addition, both sul-
fated glycosaminoglycans and RNAs have been detected in 
degenerating neurons of AD [15,17], suggesting a putative 
role in NFD. Nevertheless, it remains to determine if in 
AD, PHF are preferentially made up of Tau isoforms with 
three and/or four microtubule-binding motifs, and if Tau pro-
teins with four microtubule-binding motifs play a role among 
the types of different Tau neuronal inclusions. 
We have addressed this issue using newly developed iso-
form-specific anti-Tau antibodies, such as antibody Tau-ElO 
[18] which distinguishes Tau isoforms with four microtubule-
binding motifs from the other Tau isoforms. Moreover, AD 
PHF-Tau from brain tissue homogenates were compared to 
phosphorylated Tau proteins from PiD, a neurodegenerative 
disease where Tau proteins essentially aggregate into straight 
and random filaments in Pick's bodies and therefore typically 
different from PHF of neurofibrillary tangles of AD 
[11,19,20]. 
2. Materials and methods 
2.1. Patients 
All of the AD patients met the NINCDS-ADRDA criteria and 
were histopathologically confirmed for the definite diagnosis of AD, 
as already reported [21]. The five PiD cases were the same as those 
described by Delacourte et al. [11]. Control brain tissues, obtained 
from non-demented patients, did not display neurofibrillary pathology 
in the neocortex. AD, PiD and control brain tissue samples consisted 
of gray matter from the frontal lobe to avoid the possibility of con-
taminating aggregated Tau proteins with aggregated Tau proteins 
which are generated in the hippocampal formation during aging [22]. 
2.2. Monoclonal and polyclonal antibodies 
AD2 is a protein A-purified monoclonal antibody raised against a 
crude PHF preparation obtained from AD brain [23]. It detects NFTs 
by light microscopy [5], PHFs by electron microscopy [24] and PHF-
Tau on immunoblots [23]. It specifically recognizes phosphorylated 
serines 396 and 404 (numbering according to the longest human brain 
Tau isoform) in the carboxy-terminal part of Tau [23]. AD2 was used 
at 0.2 ug/ml in Tris-buffered saline containing 0.05% Tween-20 (TBS-
T). Tau-1 is a phospho-dependent monoclonal antibody (Boehringer 
Mannheim GmbH, Germany) recognizing Tau proteins at the un-
phosphorylated sequence 192-204 [25]. It was used at 1:5000 in 
TBS-T. 
M19G is a polyclonal antibody raised against a synthetic peptide 
corresponding to the first 19 amino acids of Tau [5,23]. Antibodies 
304, Tau-E3 and Tau-ElO are Tau isoform-specific. Polyclonal anti-
body 304, raised against the 29 amino-acid insert (exon 2) [26], was 
kindly provided by Dr. M. Goedert. Tau-E3 and Tau-ElO were both 
obtained by immunizing New Zealand rabbits with synthetic peptides 
(Neosystem, France) corresponding to the first 16 amino acids en-
coded by exon 3 and the first 10 amino acids encoded by exon 10 
of Tau, respectively. The specificity of Tau-ElO for Tau proteins with 
the translated sequence of exon 10 was already established using re-
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combinant Tau isoforms [18]. Tau-E3 specificity was also verified us-
ing the same approach (data not shown). 
These phospho-independent polyclonal antibodies recognize both 
normal Tau and PHF-Tau. M19G, 304, Tau-E3 and Tau-ElO were 
used in TBS-T at a final dilution of 1:5000, 1:1000, 1:5000 and 
1:2000, respectively. 
2.3. Monodimensional (1-D) and two-dimensional (2-D) gel 
electrophoresis 
For 1-D and 2-D gel electrophoresis, frontal brain tissue samples 
were freshly homogenized in Laemmli sample buffer (1:10) containing 
5% of SDS. Brain homogenates were aliquoted and frozen at —80°C 
until used. Each aliquot was used not more than twice. 1-D and 2-D 
were performed as already described [18,27]. Tau isoforms distribu-
tion was investigated using 7.5-15% polyacrylamide gradient gels. On 
2-D gels, isoelectric points (pi) were determined using the carbamy-
lated CPK (MW=45 kDa; pi range 4.9-7.1) of the Carbamylyte® 
calibration kit (Pharmacia) [27]. 
2.4. Western blots 
Proteins resolved on 1-D and 2-D gels were transferred onto nitro-
cellulose membranes (Hybond*81 ECL®1, 0.45 |im pore size, Amer-
sham) for 90 min at 0.8 mA/cm2 using an LKB Multiphor II Nova 
Blot (Pharmacia). Proteins were stained with Ponceau Red, in order 
to check the quality of the resolution for the 1-D and 2-D and to 
visualize the carbamylated CPK on 2-D blots. Blocking was carried 
out in TBS-T containing 5% dry milk and blots were incubated with 
the antibodies. Monoclonal and polyclonal antibodies were detected 
with horseradish peroxidase-labeled sheep anti-mouse and anti-rabbit 
immunoglobulins both adsorbed with human serum proteins (Sigma 
Immuno Chemicals), respectively. Blots were revealed by chemilumi-
nescence using the ECL® Western blotting system (Amersham). 
3. Results 
3.1. Tau in AD and PiD: monodimensional analysis 
The typical AD PHF-Tau components of 55, 64 and 69 kDa 
and an additional band of 74 kDa were immunolabeled by 
antibody AD2 (Fig. 1: AD, AD2). A vertical smear was al-
ways associated with the detection of PHF-Tau in AD brain 
tissue homogenates, as already described [18,23]. Using M19G 
antibody, both PHF-Tau and normal Tau proteins were ob-
served. The smear was moderatly immunostained and the 
74 kDa band was well visible (Fig. 1: AD, M19G). 
Tau isoform distribution was further investigated using iso-
form-specific anti-Tau antibodies. Antibody 304, specific for 
Tau proteins with the translated exon 2, immunolabeled PHF-
Tau 74, 69 and 64 kDa (Fig. 1: AD, 304). Lower MW were 
also detected with antibody 304, corresponding to normal Tau 
proteins (see 2-D Western blot analysis chapter), and catabo-
lic products. Antibody Tau-E3, raised against the exon 3 
translated sequence, detected the PHF-Tau bands 74 and 69 
(Fig. 1: AD, Tau-E3). Interestingly no smear was observed 
with both antibodies 304 and Tau-E3. Conversely, antibody 
Tau-ElO, specific for Tau proteins with exon 10 translated 
sequence [18], immunostained the 74, 69 and 64 PHF-Tau 
bands and intensively the vertical smear (Fig. 1: AD, Tau-
ElO). The Tau-ElO immunoreactive smear was very similar to 
the one observed with antibody AD2. In control brain tissue 
homogenates, normal Tau proteins are detected by Tau-1 
(Fig. 1: Ctrl; Tau-1), an antibody recognizing unphospho-
rylated Tau proteins at the epitope ranging from amino acid 
192 to 204 (numbering according to the longest Tau isoform) 
[25]. Antibody Tau-ElO labeled Tau proteins with four micro-
tubule-binding motifs and their specific carboxy-terminal 
catabolic products. The vertical smear was totally absent 
(Fig. 1: Ctrl, Tau-ElO). Isoform-specific anti-Tau antibodies 
AD Ctrl 
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Fig. 1. Immunoblotting of Tau proteins isoforms and their distribu-
tion in AD, control brain and PiD. Brain tissue homogenates of 
AD, control (Ctrl) and PiD were compared. Phosphorylated Tau 
proteins at serines 396 and 404 (numbering according to the longest 
Tau isoform) were immunolabeled with AD2. In AD they corre-
spond to the typical four PHF-Tau bands indicated by arrows 
(AD: AD2 lane; Tau 74, 69, 64, 55). In PiD they are resolved as 
two main phosphorylated Tau components (Tau 64, 55) and a less 
immunoreactive 69 kDa Tau band (PiD: AD2 lane, indicated by ar-
rowheads). Unphosphorylated Tau proteins were detected with Tau-
1 (Ctrl Tau-1). Both phosphorylated and dephosphorylated Tau 
proteins were immunostained with the antibody M19G (AD, lane 
M19G). Tau proteins with the translated sequence of exon 2, 3 and 
10 were selectively detected with antibodies 304, Tau-E3 and Tau-
ElO, respectively (AD, Ctrl, PiD: lanes 304, Tau-E3 and Tau-ElO). 
Note that Tau-ElO immunostains both PHF-Tau and a vertical 
smear in AD, while it did not stain phosphorylated Tau compo-
nents of PiD brain tissue homogenates (indicated by arrowheads). 
As well, immunostaining of normal Tau proteins with the translated 
exon 10 sequence in PiD was very light in comparison to AD and 
Ctrl brain tissue homogenates. 
detected normal Tau proteins (Fig. 1: Ctrl, 304, Tau-E3, 
Tau-ElO), but none of the antibodies immunoreacted with a 
smear in control brain tissue homogenates. 
Using the same approach, phosphorylated Tau proteins 
from PiD were investigated. AD2 immunolabehng showed 
the typical Tau doublet (Tau 55 and 64) and a faintly reactive 
69 kDa band (Fig. 1: PiD, AD2), as already described [5,11]. 
A vertical smear, less intensively labeled than in AD, was also 
visible. Using the isoform-specific anti-Tau antibodies, the 69 
kDa band was detected by antibodies 304 and Tau-E3 and the 
64 kDa band was strongly labeled with antibody 304 (Fig. 1: 
PiD, 304 and Tau-E3). Antibody Tau-ElO failed to react with 
any of the phosphorylated Tau proteins and no smear was 
visualized (Fig. 1: PiD, Tau-ElO). A weak signal was ob-
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Fig. 2. Two-dimensional characterization of the Tau isoforms distribution in AD PHF-Tau. PHF-Tau proteins from an AD brain tissue homo-
genate are resolved by 2-D gel electrophoresis and immunoblot with either the antibody M19G (A), Tau-ElO (B), 304 (C) or antibody Tau-E3. 
All the PHF-Tau components are observed with antibody M19G (A: x74, x69, T64 and x55). For each of the PHF-Tau components the Tau 
isoforms content is determined using isoform-specific anti-Tau antibodies Tau-ElO (B), 304 (C) and Tau-E3 (D), respectively. The correspond-
ing translated exons are indicated laterally by arrowheads. Note that antibody Tau-ElO (B) detect a basic vertical smear and that PHF-Tau 
with the translated sequence of exon 10 are the less acidic Tau isoforms among AD PHF-Tau proteins. Two-dimensional immunoblots are ori-
entated with the basic origin on the right and the acidic end on the left, pi 5.00 and 7.10 are indicated on the x-axis. 
served for normal Tau proteins and carboxy-terminal Tau time of exposure than for the other antibodies (AD2, 304, 
catabolic products with antibody Tau-ElO. It needed a longer Tau-E3) and for obtaining Tau-ElO signal in both AD and 
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control cases. The same results were obtained for the five PiD 
cases analysed. 
3.2. Two-dimensional Western blot analysis of AD PHF-TAU 
AD PHF-Tau are known to be hyperphosphorylated [27] 
while normal Tau proteins are dephosphorylated during post-
mortem delays [28]. Both species of Tau proteins are present 
in AD brain tissue homogenates. Therefore 2-D gel analysis 
was used to separate normal Tau from PHF-Tau, since PHF-
Tau are acid and normal Tau are basic [18]. This approach 
enabled us to define the precise Tau isoform distribution 
among AD PHF-Tau components. M19G detected six PHF-
Tau spots in the pH gradient, ranging from pi 5.5 to 7.1. 
Normal Tau proteins were not observed in this pH gradient 
since their pi was over 7.1 (Fig. 2A). The 74 kDa spot was 
detected by antibodies Tau-ElO, 304 and Tau-E3 (Fig. 2B-D). 
The 69 kDa PHF-Tau component was resolved into two 
spots. The highest and most acidic one, was immunolabeled 
by antibodies 304 and Tau-E3 (Fig. 2C,D). The lowest and 
basic one, was detected by antibodies 304 and Tau-ElO (Fig. 
2B,C). The 64 kDa PHF-Tau component was also made of 
two spots (Fig. 2A). The more intensively labeled spot, char-
acterized by the highest MW and the most acidic pi, was only 
detected by antibody 304 (Fig. 2C). The other spot was less 
acidic and was immunostained by Tau-ElO (Fig. 2B). Inter-
estingly, Tau-ElO immunoreactive Tau isoforms were the less 
acidic spots resolved by 2-D (Fig. 2B). Furthermore, the ver-
tical smear was also visualized on 2-D blots, slightly detected 
by M19G, strongly by antibodies Tau-ElO but not detected by 
antibodies 304 and Tau-E3 (Fig. 2A-D). 
4. Discussion 
2D-Gel electrophoresis coupled with Western blotting is a 
powerful approach to resolve and analyse PHF-Tau proteins, 
the structural components of neuronal inclusions in AD [18]. 
Using specific antibodies against Tau isoforms with exon 2, 3 
and 10, we were able to determine the precise isoform con-
tents of PHF-Tau of AD and the phosphorylated Tau com-
ponents of PiD. In AD brain homogenates, Tau isoforms with 
exon 10 were both observed in the soluble and the most in-
soluble bulk of PHF-Tau. Conversely, phosphorylated Tau in 
PiD were lacking of Tau isoforms with the translated exon 10 
sequence, showing a dramatic difference between these two 
types of neurofibrillary degeneration. 
In AD brain tissue homogenates, Tau proteins variants 
were distributed in numerous fractions including normal and 
PHF-Tau proteins, each group being heterogeneous because 
of their phosphorylation state [3], or resulting from other 
post-translational modifications [4], or to partial truncation 
during the catabolic process. As a consequence, Tau protein 
fractions have different immunochemical and physical proper-
ties [29,30]. 
On 2D gels, normal Tau proteins were distinguished from 
PHF-Tau, since they are dephosphorylated during post-mor-
tem delay and thus have a basidic profile [23,27,28] while 
PHF-Tau are more resistant to dephosphorylation [27] and 
remain acidic [18]. PHF-Tau could be subdivided into two 
groups: hyperphosphorylated Tau which are SDS-soluble 
(PHF sol-Tau) and composed of the whole molecule, as 
shown by their immunoreactivity with both amino- and car-
boxy-terminal specific anti-Tau antibodies. The second group 
corresponds to amino-truncated phosphorylated Tau aggre-
gates (PHF agg-Tau) not solubilized by SDS and heat treat-
ment. Therefore, they are resolved as a smear on both 1-D 
and 2-D blots while they are totally absent from control brain 
tissue homogenates, reflecting the typical neurofibrillary ag-
gregation process which occurs in AD. In addition to these 
two major groups, a third one is represented by soluble Tau 
catabolic products derived from normal and PHF agg-Tau 
[18]. 
These subgroups of Tau proteins from AD brain tissue 
likely correspond to those described in the literature [29,30]. 
However, in the present study, we addressed the question of 
the distribution of Tau isoforms among these different bulks 
of Tau. 
PHF sol-Tau were resolved as four main acidic components 
(Tau 74, 69, 64 and 55 kDa). The six isoforms expressed in the 
normal adult CNS tissue were found in the composition of 
PHF sol-Tau components [18,26], in good agreement with the 
results of Goedert et al. [26]. The 55 and 74 kDa components 
were both made of an unique Tau isoform. Tau 55 was not 
detected by antibodies against exons 2, 3 and 10 and corre-
sponds to the shortest Tau isoforms, also referred to as fetal 
Tau isoform. The 74 PHF-Tau component is immunolabeled 
by all of the isoform-specific anti-Tau antibodies and corre-
sponds to the longest Tau isoforms with amino-acid sequences 
translated from exons 2, 3 and 10. Tau 69 and 64 components 
are both made of two Tau isoforms. Tau 69 is composed of 
the Tau isoform including the two amino-terminal inserts 
(exons 2, 3) and the Tau isoforms with the amino-terminal 
insert translated from exon 2 and four microtubule-binding 
motifs (exon 10). Tau 64 is composed of isoform without 
translated sequence of exon 3 but with one amino-terminal 
translated insert (exon 2) and the isoform made of four micro-
tubule-binding motifs. The composition of PHF-Tau we de-
scribed is similar to the one resulting from in vitro phospho-
rylation of recombinant Tau protein isoforms by the protein 
kinase GSK3(3 [31]. However, it is interesting to note that Tau 
isoforms lacking exon 10 are the most acidic isoforms on 2-D 
blots, likely because the addition of the translated exon 10 
sequence, which correspond to a fourth microtubule-binding 
motif, is responsible for a less acidic character of Tau proteins 
[32]. 
Moreover, we show that Tau with four microtubule-binding 
motifs are largely integrated in the PHF agg-Tau fraction. At 
the opposite of 304 and Tau-E3 antibodies, Tau-ElO antibody 
strongly reacted with the PHF agg-Tau smear of AD brain 
tissue homogenates while immunostaining was totally absent 
in control brain tissue homogenates. Our results corroborate 
the study of Jakes et al. [33] which have shown with a differ-
ent approach that both three and four microtubule-binding 
motifs Tau isoforms are present in the PHF-core [33]. 
Furthermore, we have tested Tau-ElO antibody on brain 
tissue homogenates from five PiD cases [11]. PiD is a neuro-
degenerative disease of particular interest since intraneuronal 
aggregation of Tau is almost totally made of Pick bodies 
[8,11], a neuropathological feature easily distinguishable 
from the typical NFT observed in AD [11,19,20]. While 
AD2 shows the typical doublet of phosphorylated Tau com-
ponents (Tau 55, 64), the minor 69 kDa Tau component and a 
vertical smear [11], Tau-ElO did not stain any of the phos-
phorylated Tau doublet components, but a light immuno-
labeling was obtained for normal Tau as well as low MW 
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catabolic Tau products, after a longer time of exposure. Our 
results strongly suggest that aggregated Tau protein of Pick 
bodies are devoid of Tau isoforms made of four microtubule-
binding motifs. Those results strengthen the idea that Tau 
isoforms with exon 10 are directly implicated in the formation 
of P H F in A D for two reasons: first, because they are asso-
ciated to the most insoluble PHF-Tau fraction, which mainly 
contains the PHF-core ; second, because they are lacking in 
the composition of Pick bodies, composed of straight and 
random filaments, but not composed of P H F [34]. 
In conclusion, we show that Alzheimer's and Pick's disease 
are two neurodegenerative disorders with different types of 
neuronal inclusions that comprise different types of Tau iso-
forms. Tau isoforms with the exon 10 translated sequence are 
likely to play an important role in the formation of abnormal 
Tau filaments that constitute the neuronal inclusions. The fact 
that Tau isoforms with exon 10 are a marker of Alzheimer-
type neurofibrillary degeneration, but are not in Pick's dis-
ease, is of particular interest since the use of such isoform-
specific anti-Tau antibodies could help for an ante-mortem 
diagnosis of A D [35]. 
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